News
The OCU410ST Phase 2/3 pivotal confirmatory trial represents a major advancement as Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback